Evolent Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated January 19, 2023, details the consummation of the acquisition of the Magellan Specialty Health Division (including National Imaging Associates, Inc.) by Evolent Health, Inc. (Evolent) on January 20, 2023. The transaction was financed through a combination of new debt financing, the issuance of preferred stock, and the issuance of common stock.
Key Financial Metrics and Transaction Details
- Total Consideration: Approximately $386.7 million in cash (subject to post-closing adjustments) plus 8,474,576 shares of Class A Common Stock issued to Magellan Health, Inc.
- Debt Financing (Acquisition Facilities):
- Priority ABL Incremental Facility: $25.0 million borrowed.
- Term Loan Incremental Facility: $240.0 million borrowed.
- Total New Debt: $265.0 million.
- Equity Financing (Series A Preferred Stock):
- Shares Issued: 175,000 shares of Cumulative Series A Convertible Preferred Stock.
- Purchase Price: $960.00 per share.
- Total Gross Proceeds: $168.0 million.
- Initial Liquidation Preference: $1,000.00 per share.
- Debt Terms:
- Term Loan Interest: Adjusted Term SOFR + 6.00% or Base Rate + 5.00%.
- Revolving Loan Interest: Adjusted Term SOFR + 4.00% or Base Rate + 3.00%.
- Maturity: Earliest of the sixth anniversary of the Closing Date (approx. Jan 2029) or other specified events.
- Prepayment Penalties: 3.00% (Year 1), 2.00% (Year 2), 1.00% (Year 3), 0.00% (Year 4+).
- Preferred Stock Terms:
- Dividend Rate: Adjusted Term SOFR + 6.00% (payable quarterly in cash).
- Conversion Price: $40.00 per share of Class A Common Stock.
- Redemption: Company may not redeem prior to Jan 20, 2025. Mandatory redemption triggers include refinancing by non-affiliates or Change of Control.
Material Changes
The filing represents a material change in the Company's capital structure and asset base. Evolent has significantly increased its leverage to fund the acquisition, adding $265.0 million in secured debt and $168.0 million in preferred equity. The Company has also expanded its operations by acquiring the Magellan Specialty Health Division. The filing notes that the Company entered into an Investors Rights Agreement containing covenants limiting the incurrence of additional Funded Debt and restricted payments.
Guidance, Outlook, and Risks
This 8-K filing does not contain forward-looking guidance, revenue projections, or management commentary regarding future financial performance. However, it highlights several risks and contingencies:
- Liquidity and Debt Covenants: The new debt is subject to affirmative and negative covenants, mandatory prepayment provisions, and events of default. The Company must satisfy liquidity conditions to avoid early maturity triggers related to Junior Debt.
- Preferred Stock Restrictions: The Series A Preferred Stock includes protective covenants limiting the Company's ability to issue senior indebtedness or make restricted payments. Failure to pay dividends or breach of covenants triggers a 2.00% per annum increase in the dividend rate.
- Lock-Up Agreements: Magellan Parent is restricted from selling its acquired Class A Shares for 15 months, with partial releases at 9 and 12 months.
- Financial Statements: Pro forma financial information is provided in Exhibit 99.3, but specific consolidated revenue or profit metrics for the combined entity are not detailed in the text of this filing.
Investor Verification Checklist
- Verify the exact post-closing cash consideration amount, as the $386.7 million figure is subject to adjustments.
- Review the full text of the Credit Agreement (Exhibit 10.1) to understand specific financial covenants and liquidity requirements.
- Examine the Certificate of Designation (Exhibit 3.1) for detailed terms regarding the Series A Preferred Stock conversion and redemption mechanics.
- Analyze the Unaudited Pro Forma Financial Information (Exhibit 99.3) to assess the impact of the acquisition and new debt on the Company's leverage ratios and earnings.
- Confirm the identity of the Purchasers of the Series A Preferred Stock via Schedule I of the Securities Purchase Agreement (Exhibit 10.2).